Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.42 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7735556 | 0.82 | ALDH1A1 (0.51) | FAAHRAB9ASMN1; SMN2CREBBPALDH1A1 | |
| SCHEMBL12169426 | 0.81 | FAAH (0.40) | FAAHRAB9ASMN1; SMN2CREBBPALDH1A1 | |
| SCHEMBL13057448 | 0.76 | MAPK14 (0.55) | L3MBTL1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL8076929 | 0.76 | CREBBP (0.41) | SMN1; SMN2CREBBPALDH1A1ROCK2MEN1 | |
| SCHEMBL8079619 | 0.75 | CREBBP (0.44) | FAAHRAB9ASMN1; SMN2CREBBPALDH1A1 | |
| SCHEMBL12712495 | 0.72 | BRD4 (0.38) | FAAHCREBBPROCK2 | |
| SCHEMBL15305628 | 0.72 | FAAH (0.42) | FAAHCREBBPALDH1A1ROCK2MEN1 | |
| SCHEMBL13057462 | 0.71 | MAPK14 (0.50) | L3MBTL1RAB9AALDH1A1MAPK14NPBWR1 | |
| SCHEMBL8070679 | 0.71 | CREBBP (0.41) | L3MBTL1RAB9ASMN1; SMN2CREBBPALDH1A1 | |
| SCHEMBL9953649 | 0.71 | RAB9A (0.51) | FAAHRAB9ASMN1; SMN2CREBBPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| WO-2010147969-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147975-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147973-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2010-11-25 | — | — | US | disclosed |
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2010-11-25 | — | — | US | disclosed |
| WO-2009073779-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009032277-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | FAAH 468/4885L3MBTL1 3426/4885RAB9A 1002/4885 |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | FAAH 419/4885L3MBTL1 3790/4885RAB9A 1242/4885 |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | FAAH 419/4885L3MBTL1 3790/4885RAB9A 1242/4885 |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | FAAH 447/4885L3MBTL1 3835/4885RAB9A 1091/4885 |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | FAAH 444/4885L3MBTL1 3817/4885RAB9A 1125/4885 |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | FAAH 468/4885L3MBTL1 3426/4885RAB9A 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.